Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the presentation of results from multiple clinical studies at the 2025 European Society for Medical Oncology (ESMO) Congress, held in Berlin, Germany from October 17 to 21, 2025. The studies included data on sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate $(ADC)$, trastuzumab botidotin (A166), a HER2-directed ADC, and SKB315, a Claudin18.2 ADC. Two studies of sac-TMT were selected for Late Breaking Abstract oral presentation, including a Phase 3 study in EGFR-mutated non-small cell lung cancer following progression on EGFR-tyrosine kinase inhibitors. The company also reported ongoing research on SKB315 in combination with immunotherapy and as monotherapy in tumors expressing Claudin18.2. The company cautioned that these drugs are not yet approved for all indications and may not ultimately be successfully developed or commercialized.